(An open ended equity scheme investing in
Pharma and Healthcare sector)
(An open ended equity scheme investing in
Pharma and Healthcare sector)
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be realized.
NAV Details (As on July 31, 2026)| Regular IDCW | : ₹ 10.7646 |
| Regular Growth | : ₹ 10.7646 |
| Direct IDCW | : ₹ 10.9769 |
| Direct Growth | : ₹ 10.9769 |
Benchmark Index (Tier 1)BSE Healthcare TRI
Date of AllotmentJune 27, 2025
Fund Manager^ | Fund Manager | Managing fund since | Experience |
| Mr. Ankeet Pandya** | 10-Jul-26 | 11 years |
| Mr. Rohan Korde | 01-May-26 | 21 years |
**Mr. Ankeet Pandya was appointed as Fund Manager w.e.f July 10, 2026 in place of Mr. Sanjay Chawla.
Load Structure
Exit Load: • Redemption/ switch out of units upto 10% of the
units allotted before 1 year from date of allotment- Exit
load -NIL. • For redemption/switch out of units above 10%
of units allotted within 1 year from the date of allotment-
1.00% of applicable NAV. • For redemption/switch out of
units after 1 year from the date of allotment-Nil.
For detailed load structure please refer Scheme
Information Document.
Minimum Application Amount:
₹ 1,000 and in multiples of ₹ 1
thereafter.
Minimum Additional Purchase Amount:₹ 1,000 and in
multiples of ₹ 1 thereafter.
| Monthly AAUM## As on July 31, 2026 | : ₹ 528.31 Crores |
| AUM## As on July 31, 2026 | : ₹ 519.48 Crores |
## including inter-scheme Investments, if any, by other schemes of Baroda BNP Paribas Mutual Fund, as may be applicable
| EQUITY HOLDINGS | % of Net Assets | |
| Pharmaceuticals & Biotechnology | 71.48% | |
| ✔Sun Pharmaceutical Industries Limited | 8.82% | |
| ✔Torrent Pharmaceuticals Limited | 8.58% | |
| ✔Divi's Laboratories Limited | 6.66% | |
| ✔Lupin Limited | 6.46% | |
| ✔IPCA Laboratories Limited | 5.72% | |
| ✔Laurus Labs Limited | 5.24% | |
| ✔AstraZeneca Pharma India Limited | 4.05% | |
| ✔Glenmark Pharmaceuticals Limited | 3.44% | |
| Mankind Pharma Limited | 3.09% | |
| Aurobindo Pharma Limited | 3.04% | |
| Zydus Lifesciences Limited | 2.47% | |
| Emcure Pharmaceuticals Limited | 2.46% | |
| Abbott India Limited | 2.41% | |
| Acutaas Chemicals Limited | 2.15% | |
| Concord Biotech Limited | 2.05% | |
| Ajanta Pharma Limited | 1.40% | |
| Gland Pharma Limited | 1.20% | |
| Cipla Limited | 1.13% | |
| Dr. Reddy's Laboratories Limited | 1.11% | |
| Healthcare Services | 19.71% | |
| ✔Apollo Hospitals Enterprise Limited | 5.35% | |
| ✔Fortis Healthcare Limited | 4.55% | |
| Dr. Lal Path Labs Limited | 3.12% | |
| Aster DM Quality Care Limited | 2.53% | |
| Nephrocare Health Services Ltd | 1.74% | |
| Metropolis Healthcare Limited | 1.46% | |
| Manipal Health Enterprises Ltd | 0.96% | |
| Insurance | 2.27% | |
| Max Financial Services Limited | 2.27% | |
| IT - Services | 1.42% | |
| Inventurus Knowledge Solutions Limited | 1.42% | |
| Retailing | 1.09% | |
| MedPlus Health Services Limited | 1.09% | |
| LESS THAN 0.75% EXPOSURE | 0.64% | |
| TOTAL EQUITY HOLDING | 96.61% | |
| Total Fixed Income Holdings | ||
| TREPS, Cash & Other Net Current Assets | 3.39% | |
| GRAND TOTAL | 100.00% | |
Investment in Top 10 scrips constitutes 58.87% of the portfolio
The scheme currently does not have Distribution History.
| BER - Regular Plan (%) | 2.08% |
| BER - Direct Plan (%) | 0.61% |
| Portfolio Turnover Ratio | 0.74 |
The Total Expense Ratio (TER) is the sum of the Base
Expense Ratio (BER), brokerage fees, transaction costs, and
statutory levies.
For details of TER, please refer the TER
disclosure available on the website on
https://www.barodabnpparibasmf.in/downloads/total-expense-ratio-of-mutual-fund-schemes.
| No of Stocks | 30 |
| Portfolio RoE (%) | 16.76 |
| EPS Growth (%) | 30.72 |
➤ Long term capital appreciation.
➤ Investing predominantly in equity and equity related instruments of Pharma and Healthcare companies
*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.
^^Riskometer For Scheme: basis it’s portfolio, ^Riskometer For Benchmark (BSE Healthcare TRI): basis it’s constituents; As on July 31, 2026
For complete portfolio, kindly refer the website https://www.barodabnpparibasmf.in/
* refer Glossary page
Mutual Fund investments are subject to market risks, read all scheme related documents carefully.